Genmab
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Genmab
- Target Recruit Count
- 549
- Registration Number
- NCT05409066
- Locations
- 🇺🇸
University of Arizona Cancer Center - North Campus /ID# 228862, Tucson, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences /ID# 227198, Little Rock, Arkansas, United States
🇺🇸Alta Bates Summit Medical Center for Research /ID# 229428, Berkeley, California, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 565
- Registration Number
- NCT05283720
- Locations
- 🇺🇸
The University of Arizona Cancer Center - North Campus /ID# 242219, Tucson, Arizona, United States
🇺🇸Yale University School of Medicine /ID# 242089, New Haven, Connecticut, United States
🇺🇸Christiana Care Health Service /ID# 242301, Newark, Delaware, United States
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Genmab
- Target Recruit Count
- 17
- Registration Number
- NCT05206357
- Locations
- 🇺🇸
Lucile Packard Children's Hospital /ID# 240854, Palo Alto, California, United States
🇺🇸Nicklaus Children's Hospital /ID# 241174, Miami, Florida, United States
🇺🇸New York Medical College /ID# 239208, Valhalla, New York, United States
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
- Conditions
- B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Genmab
- Target Recruit Count
- 49
- Registration Number
- NCT05201248
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital /ID# 230520, Beijing, Beijing, China
🇨🇳Peking University Third Hospital /ID# 228138, Beijing, Beijing, China
🇨🇳Fujian Medical University Union Hospital /ID# 231890, Fuzhou, Fujian, China
GEN1047 for Solid Tumors - First in Human (FIH) Trial
- Conditions
- Ovarian Cancer, Ovarian NeoplasmsEndometrial Cancer, Endometrial NeoplasmSquamous Non Small Cell Lung Cancer (NSCLC-SCC)Breast Cancer, Breast Neoplasms
- Interventions
- Biological: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Genmab
- Target Recruit Count
- 179
- Registration Number
- NCT05180474
- Locations
- 🇺🇸
UCLA Department of Medicine Hematology Oncology, Los Angeles, California, United States
🇺🇸Yale University - Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
- Conditions
- Non Small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 125
- Registration Number
- NCT05117242
- Locations
- 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Florida Cancer Specialists - FCS South, Fort Myers, Florida, United States
🇺🇸Florida Cancer Center, Saint Petersburg, Florida, United States
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genmab
- Target Recruit Count
- 18
- Registration Number
- NCT04937153
- Locations
- 🇯🇵
National Cancer Center East, Chiba, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)Diffuse Large B Cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 130
- Registration Number
- NCT04824794
- Locations
- 🇳🇿
North Shore Hospital, Takapuna, New Zealand
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
- Conditions
- Diffuse Large B-Cell LymphomaFollicular Lymphoma
- Interventions
- Drug: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 543
- Registration Number
- NCT04663347
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Drug: Investigator's Choice Chemotherapy
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 552
- Registration Number
- NCT04628494
- Locations
- 🇺🇸
Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
🇺🇸Community Health Network Cancer Center North, Indianapolis, Indiana, United States
🇺🇸University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States